Leading and higher twists in the proton polarized structure function at large Bjorken x

A phenomenological parameterization of the proton polarized structure function has been developed for x > 0.02 using deep inelastic data up to ~ 50 (GeV/c)**2 as well as available experimental results on both photo- and electro-production of proton resonances. According to the new parameterization the generalized Drell-Hearn-Gerasimov sum rule is predicted to have a zero-crossing point at Q**2 = 0.16 +/- 0.04 (GeV/c)**2. Then, low-order polarized Nachtmann moments have been estimated and their Q**2-behavior has been investigated in terms of leading and higher twists for Q**2 > 1 (GeV/c)**2. The leading twist has been treated at NLO in the strong coupling constant and the effects of higher orders of the perturbative series have been estimated using soft-gluon resummation techniques. In case of the first moment higher-twist effects are found to be quite small for Q**2 > 1 (GeV/c)**2, and the singlet axial charge has been determined to be a0[10 (GeV/c)**2] = 0.16 +/- 0.09. In case of higher order moments, which are sensitive to the large-x region, higher-twist effects are significantly reduced by the introduction of soft gluon contributions, but they are still relevant at Q**2 ~ few (GeV/c)**2 at variance with the case of the unpolarized transverse structure function of the proton. Our finding suggests that spin-dependent correlations among partons may have more impact than spin-independent ones. As a byproduct, it is also shown that the Bloom-Gilman local duality is strongly violated in the region of polarized electroproduction of the Delta(1232) resonance.Comment: revised version to appear in Phys. Rev. D; extended discussion on the generalized DHG sum rul

Magnetic shielding accelerates the proliferation of human neuroblastoma cell by promoting G1-phase progression

Organisms have been exposed to the geomagnetic field (GMF) throughout evolutionary history. Exposure to the hypomagnetic field (HMF) by deep magnetic shielding has recently been suggested to have a negative effect on the structure and function of the central nervous system, particularly during early development. Although changes in cell growth and differentiation have been observed in the HMF, the effects of the HMF on cell cycle progression still remain unclear. Here we show that continuous HMF exposure significantly increases the proliferation of human neuroblastoma (SH-SY5Y) cells. The acceleration of proliferation results from a forward shift of the cell cycle in G1-phase. The G2/M-phase progression is not affected in the HMF. Our data is the first to demonstrate that the HMF can stimulate the proliferation of SH-SY5Y cells by promoting cell cycle progression in the G1-phase. This provides a novel way to study the mechanism of cells in response to changes of environmental magnetic field including the GMF

Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease

BACKGROUND Ustekinumab, a monoclonal antibody to the p40 subunit of interleukin-12 and inter-leukin-23, was evaluated as an intravenous induction therapy in two populations with moderately to severely active Crohn’s disease. Ustekinumab was also evaluated as subcutaneous maintenance therapy. METHODS We randomly assigned patients to receive a single intravenous dose of ustekinumab (either 130 mg or approximately 6 mg per kilogram of body weight) or placebo in two induction trials. The UNITI-1 trial included 741 patients who met the criteria for primary or secondary nonresponse to tumor necrosis factor (TNF) antagonists or had unacceptable side effects. The UNITI-2 trial included 628 patients in whom conventional therapy failed or unacceptable side effects occurred. Patients who completed these induction trials then participated in IM-UNITI, in which the 397 patients who had a response to ustekinumab were randomly assigned to receive subcutaneous maintenance injections of 90 mg of ustekinumab (either every 8 weeks or every 12 weeks) or placebo. The primary end point for the induction trials was a clinical response at week 6 (defined as a decrease from baseline in the Crohn’s Disease Activity Index [CDAI] score of ≥100 points or a CDAI score <150). The primary end point for the maintenance trial was remission at week 44 (CDAI score <150). RESULTS The rates of response at week 6 among patients receiving intravenous ustekinumab at a dose of either 130 mg or approximately 6 mg per kilogram were significantly higher than the rates among patients receiving placebo (in UNITI-1, 34.3%, 33.7%, and 21.5%, respectively, with P≤0.003 for both comparisons with placebo; in UNITI-2, 51.7%, 55.5%, and 28.7%, respectively, with P<0.001 for both doses). In the groups receiving maintenance doses of ustekinumab every 8 weeks or every 12 weeks, 53.1% and 48.8%, respectively, were in remission at week 44, as compared with 35.9% of those receiving placebo (P = 0.005 and P = 0.04, respectively). Within each trial, adverse-event rates were similar among treatment groups. CONCLUSIONS Among patients with moderately to severely active Crohn’s disease, those receiving intravenous ustekinumab had a significantly higher rate of response than did those receiving placebo. Subcutaneous ustekinumab maintained remission in patients who had a clinical response to induction therapy. (Funded by Janssen Research and Development; ClinicalTrials.gov numbers, NCT01369329, NCT01369342, and NCT01369355.

ATHENA detector proposal - a totally hermetic electron nucleus apparatus proposed for IP6 at the Electron-Ion Collider

ATHENA has been designed as a general purpose detector capable of delivering the full scientific scope of the Electron-Ion Collider. Careful technology choices provide fine tracking and momentum resolution, high performance electromagnetic and hadronic calorimetry, hadron identification over a wide kinematic range, and near-complete hermeticity.This article describes the detector design and its expected performance in the most relevant physics channels. It includes an evaluation of detector technology choices, the technical challenges to realizing the detector and the R&D required to meet those challenges

Semi-inclusive pi(0) target and beam-target asymmetries from 6 GeV electron scattering with CLAS

We present precision measurements of the target and beam-target spin asymmetries from neutral pion electroproduction in deep-inelastic scattering (DIS) using the CEBAF Large Acceptance Spectrometer (CLAS) at Jefferson Lab. We scattered 6-GeV, longitudinally polarized electrons off longitudinally polarized protons in a cryogenic $^{14}$NH$_3$ target, and extracted double and single target spin asymmetries for $ep\rightarrow e^\prime\pi^0X$ in multidimensional bins in four-momentum transfer ($1.0<Q^2<3.2$ GeV$^2$), Bjorken-$x$ ($0.12<x<0.48$), hadron energy fraction ($0.4<z<0.7$), transverse pion momentum ($0<P_T<1.0$ GeV), and azimuthal angle $\phi_h$ between the lepton scattering and hadron production planes. We extracted asymmetries as a function of both $x$ and $P_T$, which provide access to transverse-momentum distributions of longitudinally polarized quarks. The double spin asymmetries depend weakly on $P_T$. The $\sin 2\phi_h$ moments are zero within uncertainties, which is consistent with the expected suppression of the Collins fragmentation function. The observed $\sin\phi_h$ moments suggest that quark gluon correlations are significant at large $x$.Comment: 18 preprint pages, 3 figure

ATHENA detector proposal — a totally hermetic electron nucleus apparatus proposed for IP6 at the Electron-Ion Collider

ATHENA has been designed as a general purpose detector capable of delivering the full scientific scope of the Electron-Ion Collider. Careful technology choices provide fine tracking and momentum resolution, high performance electromagnetic and hadronic calorimetry, hadron identification over a wide kinematic range, and near-complete hermeticity. This article describes the detector design and its expected performance in the most relevant physics channels. It includes an evaluation of detector technology choices, the technical challenges to realizing the detector and the R&amp;D required to meet those challenges